Ketamine is an NMDA-receptor antagonist that has been on the U.S. market as an anesthetic since 1970. In the early 2000s, NIH-funded work demonstrated that sub-anesthetic doses (~0.5 mg/kg IV over 40 minutes) produce rapid and substantial…
MEMBERS ONLY
Continue Reading
This article is available to Vanguard members. Join to access all physician-curated content.